Article
作者: Carvajal, Richard ; Reynolds, Aimee ; Sullivan, Ryan J ; Handel, Eleanor E ; Richly, Heike ; Sharaby, Sherif ; Milanez-Almeida, Pedro ; Speetjens, Frank M ; Otero, Javier A ; Ramelyte, Egle ; Sandhu, Shahneen ; Yerramilli-Rao, Padmaja ; Wei, Alexander Z ; RamKumar, Thiruvamoor ; Carlino, Matteo S ; Kee, Damien ; Smithy, James ; Hassel, Jessica C ; Shoushtari, Alexander N ; Hoffmaster, Keith ; Gromke, Tanja ; Calvo, Emiliano ; Werner, Lillian ; Ramon-Patino, Jorge ; Ising, Mary ; Enk, Alexander ; Kapiteijn, Ellen ; Chaudhury, Anwesha ; Piperno-Neumann, Sophie ; Dummer, Reinhard ; Rodrigues, Manuel ; Montazeri, Kamaneh
Abstract:
Metastatic uveal melanoma (mUM) is an aggressive cancer with limited treatment options; 85−90% of tumors harbor activating
GNAQ
and
GNA11
mutations. Uveal melanoma cells also express PMEL (also known as PMEL17 or gp100), a melanocyte lineage antigen. DYP688, a novel biology-matched antibody−drug conjugate, binds surface PMEL and delivers the potent Gα
q
/Gα
11
(G
q/11
) inhibitor SDZ475 as payload by internalization. This dose-escalating first-in-human phase 1 study of DYP688 in patients with metastatic uveal melanoma and other
GNAQ
/
GNA11
-mutant melanomas assessed safety as the primary endpoint and pharmacokinetics and preliminary antitumor activity as secondary endpoints. Sixty-six patients received varying DYP688 doses and schedules. Grade 3 treatment-related adverse events occurred in five patients (7.6%), including one dose-limiting toxicity of grade 3 hypotension. Objective responses were seen in 13 out of 66 patients (19.7%) and tumor reduction in 47 out of 66 patients (71.2%). Median progression-free survival was 7.2 (95% CI: 5.3–7.8) months. In summary, DYP688 was well tolerated and showed preliminary efficacy, supporting this novel therapeutic approach. ClinicalTrials.gov identifier:
NCT05415072
.